Significance of PHQ-9 Score for Depression

PHQ-9 Scoring and Clinical Significance

A PHQ-9 score of 8 or higher is considered significant for depression, based on validated studies in clinical populations 1, 2, 3
The American Society of Clinical Oncology guideline recommends a cutoff score of 8 for detecting clinically significant depression, supported by meta-analysis data 1, 3
A score of 1-7 indicates minimal symptoms of depression, with patients typically having effective coping skills and access to social support 1, 3, 4
A score of 8-14 represents moderate depressive symptomatology, requiring attention and indicating subthreshold depressive symptoms, with functional impairment ranging from mild to moderate 1, 2, 3
A score of 15-19 indicates moderate to severe depressive symptomatology, with symptoms interfering moderately to markedly with functioning, and referral to psychology and/or psychiatry for diagnosis and treatment is recommended 1, 3, 4
A score of 20-27 indicates severe depressive symptomatology, requiring immediate intervention, with significant functional impairment present 1, 3, 4

The American Society of Clinical Oncology guideline specifically recommends a cutoff score of 8 based on diagnostic accuracy studies with cancer outpatients, supported by meta-analysis data from Manea et al. 1, 3

Self-harm assessment is important, particularly with higher scores, and the frequency and specificity of thoughts of self-harm are most important for risk assessment 1, 2
A phased screening approach is recommended, including identifying presence/absence of pertinent history or risk factors, screening with the first two items of PHQ-9, and completing the full PHQ-9 if either of the first two items scores ≥2 1, 3
Clinical context should be considered when interpreting PHQ-9 scores, including duration of symptoms, associated sociodemographic factors, psychiatric or health comorbidities, and social impairments 1, 3, 4
Culturally sensitive assessments should be used when possible, and tailored assessment for those with learning disabilities or cognitive impairments is recommended 4

For patients with a PHQ-9 score ≥8, evaluation for functional impairment, consideration of consultation with psychology or psychiatry for diagnostic confirmation, and assessment for risk of self-harm are recommended 1, 2
Referral to psychology and/or psychiatry for diagnosis and treatment is strongly recommended for scores ≥15 1, 4

A phased screening approach is recommended, starting with the first two PHQ-9 items (anhedonia and depressed mood), and if either scores ≥2, complete the full PHQ-9 assessment, as suggested by the Journal of Clinical Oncology guidelines 5
Special attention should be given to item 9 regarding self-harm thoughts; the frequency and specificity of these thoughts are crucial for risk assessment, according to the Journal of Clinical Oncology 5

For scores 8-14, consider low-intensity interventions such as guided self-help based on cognitive behavioral therapy, structured physical activity programs, or pharmacologic treatment as appropriate, as recommended by the Journal of Clinical Oncology 5
For scores ≥15, high-intensity interventions delivered by licensed mental health professionals are recommended, including individual psychological therapy using treatment manuals that incorporate cognitive change, behavioral activation, and biobehavioral strategies, as suggested by the Journal of Clinical Oncology 5
For any patient identified as at risk of harm to self or others, immediate referral for emergency evaluation by a licensed mental health professional is required, according to the Journal of Clinical Oncology 5

Failing to complete the full PHQ-9 when initial screening items suggest depression, as warned by the Journal of Clinical Oncology 5
Omitting the self-harm item (item 9) from assessment, which may artificially lower scores and miss critical risk information, as cautioned by the Journal of Clinical Oncology 5

A phased screening strategy starting with the first two PHQ-9 items (anhedonia and depressed mood) is recommended, and only complete the full 9-item questionnaire if either item scores ≥2, as assessed in patients with various conditions 6
The two screening questions assess little interest or pleasure in doing things (anhedonia) and feeling down, depressed, or helpless (depressed mood), with a score of ≥2 indicating the need for further assessment 6
If both items score 0-1, the screen is negative and no further assessment is needed, as supported by evidence from patients in different clinical settings 7, 6

Never omit item 9 regarding self-harm thoughts, as this artificially lowers scores and misses critical risk information, emphasizing the importance of thorough assessment 6
If any self-harm ideation is endorsed, immediate referral for emergency psychiatric evaluation is required regardless of total PHQ-9 score, highlighting the need for prompt intervention 6

For scores 8-14 (Moderate Depression), initiate low-intensity interventions including individually guided self-help based on cognitive behavioral therapy (CBT) with behavioral activation and problem-solving, as recommended by clinical guidelines 6
For scores 15-27 (Moderately Severe to Severe Depression), immediate referral to psychology and/or psychiatry for formal diagnosis and treatment is mandatory, with high-intensity interventions delivered by licensed mental health professionals 6

The PHQ-9 loses accuracy in patients with cognitive impairment, and alternative assessment methods should be used in this population, such as informant-based tools like the AD8 8
Culturally sensitive assessments should be used when possible, and evaluation should be tailored for patients with learning disabilities or cognitive impairments, ensuring equitable care 6
Detecting depression in older adults is particularly challenging and may require additional clinical judgment, emphasizing the need for careful evaluation 6

Administer the PHQ-9 at initial diagnosis or start of treatment, regular intervals during treatment, and 3, 6, and 12 months after treatment completion, as well as during times of personal transition or family crisis, to monitor depression symptoms 6
The PHQ-9 should also be administered when approaching end of life in palliative care settings, to ensure comprehensive care 7, 9